First Author: I.Chatziralli GREECE
Co Author(s): T. Sergentanis M. Moschos A. Jaulim P. Dimitriadis P. Mitropoulos P. Kiryttopoulos 0 0 0 0 0 0 0 0 0
Back to previous
To evaluate the effect of intravitreal ranibizumab in central serous chorioretinopathy (CSR) by meta-analysis.
1Laboratory of Electrophysiology, 1st Department of Ophthalmology, University of Athens, Athens, Greece 22nd Eye Clinic, Ophthalmiatrion Athinon 3Department of Epidemiology and Biostatistics, University of Athens, Athens, Greece 4Royal Derby Hospital NHS Foundation Trust, Derby, East Midlands, UK 5Department of Internal Medicine, General Hospital of Veroia, Veroia, Greece
Clinical controlled studies that assessed the effect of intravitreal ranibizumab in CSR were identified through systematic search of PubMed and the Cochrane Central Register of Controlled Trials. Data on best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded and compared with those treated either by simple observation or by the gold standard treatment i.e., photodynamic therapy (control group).
Three clinical trials were included in the meta-analysis, while case reports and small case series were excluded. The intravitreal ranibizumab injection achieved better BCVA, although did not reach statistically significant differences in comparison to control group at 6 months after injection. Additionally, there was no statistically significant difference between the ranibizumab group and the control group as far as the CMT is concerned at the end of the follow-up period.
Meta-analysis, based on the current published literature, showed lack of positive effect of intravitreal ranibizumab in the treatment of CSR.